Praxis Precision Medicines to Participate in September Investor Conferences

Rhea-AI Summary

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on CNS disorders, has announced its participation in three major investor conferences in September 2025:

• Baird Global Healthcare Conference - Corporate presentation on September 9th at 9:00 AM EDT
• H.C. Wainwright Global Investment Conference - Fireside chat on September 10th at 8:30 AM EDT
• TD Cowen Novel Mechanisms Summit - Virtual presentation on September 18th at 3:00 PM EDT

One-on-one meetings will be available at all events, and webcasted presentations will be accessible through the company's website for 90 days.

BOSTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that Praxis’ management will be attending and presenting in three upcoming investor conferences:

• Baird 2025 Global Healthcare Conference: a corporate presentation will take place on Tuesday, September 9th at 9:00-9:35am EDT at the InterContinental New York Barclay.
• H.C. Wainwright 27th Annual Global Investment Conference: a fireside chat will be held on Wednesday, September 10th at 8:30am EDT at the Lotte New York Palace Hotel in New York City. A live webcast of the fireside chat will be available through this link.
• TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit: a corporate presentation will take place virtually on Thursday, September 18th at 3:00-3:30pm EDT.

The Company will be available for one-on-one meetings during all events. Interested investors should contact their respective representatives to request meetings.

A replay of the webcasted event will also be available through the “Events & Presentations” page under the “Investors + Media” section of the company’s website for 90 days.

About Praxis  
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.

Investor Contact: 
Praxis Precision Medicines 
investors@praxismedicines.com 
857-702-9452 
 
Media Contact:
Dan Ferry
Life Science Advisors
Daniel@lifesciadvisors.com
617-430-7576

FAQ

When is Praxis Precision Medicines (PRAX) presenting at the Baird Global Healthcare Conference 2025?

Praxis will give a corporate presentation at the Baird Conference on Tuesday, September 9th, 2025 from 9:00-9:35 AM EDT at the InterContinental New York Barclay.

How can investors access Praxis Precision Medicines' (PRAX) conference presentations?

Investors can access the webcasted presentations through the 'Events & Presentations' page under the 'Investors + Media' section of Praxis' website. Replays will be available for 90 days.

What types of meetings is Praxis Precision Medicines (PRAX) offering at the September 2025 conferences?

Praxis is offering one-on-one meetings with investors during all three conferences. Interested investors should contact their respective representatives to schedule meetings.

What is Praxis Precision Medicines' (PRAX) main focus as a company?

Praxis is a clinical-stage biopharmaceutical company that develops therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, translating genetic insights into treatments.